Latest News and Press Releases
Want to stay updated on the latest news?
Featured Releases
-
EXECUTIVE SUMMARY VALLAURIX Research, Development & Innovation Centre to expand its existing facilities and capabilities core focus on accelerating development of liquid long-acting drug delivery...
Read More -
Svitzer signs agreement with Cochin Shipyard to build electric TRAnsverse 2600e tugboats in India
Read More
-
Edelson Lechtzin LLP is investigating data breach claims regarding a recent cybersecurity incident at Petco Health and Wellness Company, Inc.
-
DALY 2-EU 结果显示,针对复发/难治性大 B 细胞淋巴瘤 (r/r LBCL) 患者,zamtocabtagene autoleucel (zamto-cel) 与化疗免疫疗法相比展现出显著临床优势1大多数患者对 Zamto-cel 耐受性良好。 DALY 2-EU 将高风险群体纳入研究范围,其特点为年龄较大且具有临床高风险疾病特征12 天的制备周期使得从静脉采血到回输的全流程缩短至...
-
EXECUTIVE SUMMARY VALLAURIX Research, Development & Innovation Centre to expand its existing facilities and capabilities core focus on accelerating development of liquid long-acting drug delivery...
-
Svitzer signs agreement with Cochin Shipyard to build electric TRAnsverse 2600e tugboats in India
-
Spokane, WA, Dec. 07, 2025 (GLOBE NEWSWIRE) -- HeroFlow, the Spokane-based technology firm focused on AI-driven customer communication, today announces an expanded nationwide rollout of The AI...
-
The first batch of knockdowns for FX Super One MPV have successfully arrived at the Port of Long Beach, cleared customs and have commenced delivery to the Company’s manufacturing facility in Hanford,...
-
NEWPORT BEACH, Calif., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Caleb Downs from The Ohio State University has been named winner of the Lott IMPACT® Trophy presented by Allied Universal®. A junior safety...
-
SINGAPORE, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Digital Realty (NYSE: DLR), the largest global provider of cloud- and carrier-neutral data center, colocation, and interconnection solutions and an...
-
SINGAPORE , Dec. 07, 2025 (GLOBE NEWSWIRE) -- OPay, a leader in emerging market digital banking headquartered in Singapore, has appointed James Perry as Chief Financial Officer (CFO), effective...
-
Preliminary clinical evidence of Lisaftoclax overcoming venetoclax resistance in myeloid malignancies with a 31.8% overall response rate(ORR) in this subgroup of patients80% ORR achieved in newly...